Efficacy News and Research

RSS

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

24 Feb 2011

New vaccine offers hope against Hepatitis C

Immunology: Three percent of the world's population is currently infected by hepatitis C. The virus hides in the liver and can cause cirrhosis and liver cancer, and it's the most frequent cause of liver transplants in Denmark.

24 Feb 2011

FDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S. Prescribing Information for adult type 2 diabetes patients.

24 Feb 2011

EpiCept 2010 fourth quarter net loss is $0.06 per share

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2010, and provided an update on its key business initiatives.

24 Feb 2011

Xenogenics retains Emmes to assist with development, execution of its capital formation strategy

Xenogenics Corporation, a majority owned subsidiary of MultiCell Technologies, Inc., is pleased to announce it has retained the Emmes Group to assist with the development and execution of its capital formation strategy to help finance expanded human clinical trials of its Ideal BioStent.

24 Feb 2011

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

Novo Nordisk announced today that a Biologic License Application has been submitted to the U.S. Food and Drug Administration requesting the approval of a recombinant factor XIII compound for the vast majority of patients with congenital factor XIII deficiency, an inherited bleeding disorder.

From Novo Nordisk 23 Feb 2011

Trevena commences TRV120027 Phase 2a trial in patients with acute heart failure

Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor ligand, the first biased ligand designed to treat patients with acute heart failure.

23 Feb 2011

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A and related property rights from an affiliate of Kentucky Bioprocessing LLC and has initiated a program, based on its iBioLaunch platform, to develop an improved version of the enzyme for therapy of Fabry disease.

23 Feb 2011

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

Aestus Therapeutics, Inc., announced today that it has initiated screening of patients for a clinical trial to evaluate the efficacy of its novel pain therapeutic, ATx08-001. This placebo-controlled, two-dose level study will test the efficacy of ATx08-001 in reducing the pain following an outbreak of shingles.

23 Feb 2011

Diabetes technology granted patent in Australia

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) a global company pioneering the development of a cell implant therapy to treat diabetes and neurodegenerative diseases, has been granted a patent by the Australian Patent Office for IMMUPEL(tm), LCT's industry-leading technology for encapsulating living cells prior to transplantation.

23 Feb 2011

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

Tranzyme Pharma and Norgine B.V., have initiated dosing of ulimorelin in the first of two, Phase 3 pivotal studies - ULISES. Ulimorelin is Tranzyme's intravenous promotility agent in development for the management of postoperative ileus in hospital and acute care settings.

23 Feb 2011

Antiepileptic drugs could make HIV drugs less effective

A Michigan State University researcher is looking to uncover the risks of treating seizures in HIV-positive patients, providing much-needed data on possible interactions between antiepileptic drugs and antiretroviral medicines that potentially could make HIV drugs less effective or the disease itself drug resistant.

23 Feb 2011

Omeros announces license agreement with Daiichi Sankyo for PDE7 inhibitors

Omeros Corporation today announced that its exclusive license to phosphodiesterase 7 inhibitors from Daiichi Sankyo Co., Ltd. has been amended to include addiction and compulsive disorders in the field of use.

23 Feb 2011

Cerasome filled molecular-sized bubbles to target liver cancer cells

Nanotechnology may open a new door on the treatment of liver cancer, according to a team of Penn State College of Medicine researchers. They used molecular-sized bubbles filled with chemotherapy drugs to prevent cell growth and initiate cell death in test tubes and mice.

23 Feb 2011

Tifacogin administration shows no treatment benefit in patients with severe CAP

Use of the blood clot-inhibiting medication tifacogin does not appear to improve outcomes of patients with severe community-acquired pneumonia, according to a study conducted by researchers from North and South America, Europe, Asia and Africa. The drug had shown some potential benefit in the sCAP subgroup of an earlier trial involving sepsis patients.

23 Feb 2011

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

Harbor BioSciences, Inc., which is investigating the use the company's proprietary compound Triolex as a treatment for Parkinson's disease with funding from The Michael J. Fox Foundation, announced positive results in initial preclinical studies.

23 Feb 2011

USPTO issues Notice of Allowance to Somaxon's Silenor patent application

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for claims in U.S. patent application no. 11/781,165.

23 Feb 2011

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.

22 Feb 2011

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination with gemcitabine in patients with previously untreated, metastatic, pancreatic cancer.

22 Feb 2011

Nitroglycerin ointment may help in improving older women’s bone health: Study

A new study has shown that nitroglycerin ointment, that is used for chest pain or angina can be beneficial in postmenopausal women in improving their bone density. In this group of women, the bone becomes increasingly weak and brittle and leads to easy fractures. The study showed that postmenopausal women who used it for 2 years showed a modest increase in bone mineral density and decrease in bone resorption (loss). The study was published in the February 23 issue of JAMA.

22 Feb 2011